Artelo Biosciences, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

ORGANIZATION AND DESCRIPTION OF BUSINESS (Detail Narrative)

ORGANIZATION AND DESCRIPTION OF BUSINESS (Detail Narrative) - USD ($)			1 Months Ended	3 Months Ended						9 Months Ended
	Sep. 04, 2025	May 01, 2025	Jul. 18, 2025	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024	Oct. 28, 2025	Jun. 12, 2025	Dec. 31, 2024
Interest rate												12.00%
Common stock, par value				$ 0.001						$ 0.001		$ 0.001		$ 0.001
Net loss				$ (3,120,000)	$ (3,221,000)	$ (2,372,000)	$ (1,132,000)	$ (2,433,000)	$ (2,483,000)	$ (8,713,000)	$ (6,048,000)
Number of shares issued, shares				50,858
Common stock, shares authorized				500,000,000						500,000,000				500,000,000
Common Stock, Shares Outstanding				1,555,493						1,555,493				567,582
Preferred stock, shares authorized				69,444						69,444				69,444
Sale of stock										$ 75,000,000
Proceeds from sale of stock										4,391,000	$ 55,000
Gross proceeds from issuance of warrants										1,425,000
Warrant Share transaction costs				$ 346,000						346,000
Proceeds from issuance of warrants										1,079,000
Aggregate value										75,000,000
Cash and cash equivalents				$ 1,720,000						1,720,000
Public float less than										$ 75,000,000
Unsecured Convertible Notes [Member]
Interest rate		12.00%
Gross proceeds		$ 900,000
Conversion price		$ 6.24
Acquisition of notes by related party		$ 350,000
Private Placement [Member]
Number of shares issued, shares										136,843
Exercise price										$ 5.82
5.82 Warrant [Member]
Number of shares issued, shares										460,046
Exercise price										$ 5.82
10.00Warrant [Member]
Number of shares issued, shares										230,023
Exercise price										$ 10.00
Reserven Stock Split Member
Common stock, shares authorized				8,333,333						8,333,333			50,000,000
Common Stock, Shares Outstanding				546,667						546,667			3,280,000
Preferred stock, shares authorized				69,444,000						69,444,000			416,667,000
Pre-funded Warrants [Member]
Common stock, par value	$ 0.001			$ 0.001						$ 0.001
Number of shares issued, shares	40,894									93,180
Exercise price	$ 4.399									$ 5.819
Certificate of Change [Member]
Common stock, par value													$ 0.001
Securities purchase agreement [Member]
Equity offering description										purchase and sale of securities at a price of $10.45 per unit, consisting of: (a) 906,687 shares of common stock (or pre-funded warrants in lieu thereof); (b) three-year warrants to purchase 906,687 shares of common stock at an exercise price of $10.20 per share; and (c) three-year warrants to purchase 906,687 shares of common stock at an exercise price of $50.00 per share
Proceeds from sale of stock										$ 9,475,000
Underwriting Agreement [Member]
Number of shares issued, shares	640,924
Exercise price	$ 4.40
Equity offering description										(i) 640,924 shares of common stock at a price to the public of $4.40 per share, and (ii) pre-funded warrants to purchase up to 40,894 shares of common stock at an exercise price of $0.001 per share, at a price to the public of $4.399 per pre-funded warrant
Proceeds from sale of stock										$ 2,870,000
Gross proceed										3,000,000
Offering expenses										$ 130
Bottom [Member] \| Reserven Stock Split Member
Common stock, shares authorized				8,333,333						8,333,333
Top [Member] \| Reserven Stock Split Member
Common stock, shares authorized				500,000,000						500,000,000
Sales Agreement [Member]
Number of shares issued, shares										50,858
Proceeds from sale of stock										$ 442
Authorized capacity of ATM program			$ 6,500,000